About 14,163 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  3,612 results

Pregnancy and neonatal outcomes in women with axial spondyloarthritis: pooled data anal...
Annals of the Rheumatic Diseases; Meissner Y, Strangfeld A et. al.

Aug 13th, 2022 - To investigate outcome and course of pregnancies in women with axial spondyloarthritis (axSpA) in a pooled data analysis of pregnancy registries in rheumatology. Prospectively followed women with axSpA, fulfilling ASAS classification criteria and ...

Levels of Peripheral Th17 Cells and Th17-Related Cytokines in Patients with Ankylosing ...
Advances in Therapy; Su QY, Zheng JW et. al.

Aug 13th, 2022 - Ankylosing spondylitis (AS) is a chronic inflammatory disease. Several proinflammatory cytokines produced by T helper 17 (Th17) cells are involved in the pathogenesis of AS. We performed a meta-analysis to determine the levels of Th17 cells and se...

The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a pro...
Clinical Rheumatology; Swart IAP, Visman IM et. al.

Aug 13th, 2022 - Biologicals, such as anti-tumor necrosis factor (anti-TNF), reduce cardiovascular disease (CVD) in patients with inflammatory rheumatic diseases. Impaired renal function is a known predictor of CVD and elevated in ankylosing spondylitis (AS). To a...

Optic neuritis following COVID-19 vaccination: Do autoimmune diseases play a role?
European Journal of Ophthalmology; Pirani V, Pelliccioni P et. al.

Aug 13th, 2022 - We report two cases of optic neuritis following Pfizer-BioNTech COVID-19 vaccination in patients with autoimmune diseases. Post-vaccine optic neuritis, although rare, is reported in the literature and an autoimmune mechanism seems to be involved, ...

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Aug 12th, 2022 - The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).

see more →

Guidelines  11 results

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients ...
Pain Physician; Kaye AD, Manchikanti L et. al.

Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...

The effectiveness, safety, and economic evaluation of Korean medicine for unexplained i...

Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.

Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...

EULAR recommendations for cardiovascular disease risk management in patients with rheum...
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.

Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...

see more →

Drugs  883 results see all →

Clinicaltrials.gov  377 results

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Aug 12th, 2022 - The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

Aug 12th, 2022 - PsA is a chronic inflammatory musculoskeletal disease that has 6 disease domains, and axial disease represents one of the domains. Guselkumab is a fully human immunoglobulin (Ig) G1 lambda monoclonal antibody (mAb) that by binding to the p19 prote...

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries

Aug 12th, 2022 - Major orthopedic procedures, including total joint replacement and spine surgeries, are among the most common procedures in the population. Learning about how often these surgeries are performed can give indications of whether the treatment of art...

A Study to Assess Disease Activity in Adult Participants With Ankylosing Spondylitis Who Receive Upadacitinib in a Real-world Setting

Aug 9th, 2022 - Axial spondyloarthritis (axSpA), which encompasses radiographic axSpA (r-axSpA, also known as ankylosing spondylitis [AS]) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chroni...

Progression of Spinal Fusion in Ankylosing Spondylitis

Aug 9th, 2022 - Spinal fusion is the clinical, radiological, and pathological hallmark of ankylosing spondylitis (AS). However, spinal fusion occurs slowly in AS. Serial radiographs rarely show changes over 2 years, and often 5 or more years are needed to demonst...

see more →

News  772 results

FDA Approves Adalimumab-bwwd Biosimilar (Hadlima) in High-Concentration Form

Aug 17th, 2022 - The US Food and Drug Administration today approved a citrate-free, high-concentration formulation of adalimumab-bwwd (Hadlima), the manufacturer, Samsung Bioepis, and its commercialization partner Organon said in an announcement. Hadlima is a bios...

PsA: Long-term retention, efficacy, and safety of secukinumab in real world

Jul 31st, 2022 - Key clinical point: Secukinumab demonstrated high retention rates, sustained efficacy, and a favorable safety profile for at least 2 years after initiation in a real-world population of patients with moderate-to-severe psoriatic arthritis (PsA). M.

Psoriatic Arthritis and the Disease Activity Measures Used in Practice and Clinical Trials

Jul 20th, 2022 - This transcript has been edited for clarity. Stanley Cohen, MD: I am Dr Stanley Cohen and welcome to Medscape's InDiscussion series on psoriatic arthritis. This is episode 1 of the second season. Today we'll be discussing outcome measures, the dis...

Treat-to-Target With Tapering Proves Effective in PsA, AxSpA

Jun 28th, 2022 - Aiming for a disease activity target while reducing biologic therapy could be a winning approach for patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), according to the results of a new study presented at the annual Europ...

Upadacitinib Recommended for Nonradiographic AxSpA in Europe

Jun 28th, 2022 - Upadacitinib may soon be used for the treatment of nonradiographic axial spondyloarthritis (nr-axSpA) after the European Medicines Agency's Committee for Medicinal Products for Human Use gave it its stamp of approval last week. AbbVie, the drug's ...

see more →

Patient Education  10 results see all →